Antoaneta Balabanov, MD
Neurology · Chicago, ILNPI 1770578304
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Neurelis, Inc. at 55.8% of the total. Reporting peaked in 2023 at $4,761 and has fallen 96.3% since, to $177 in 2024.
Across 23 payments — averaging $360.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$5K
- Livanova USA, Inc.$2K
- Medtronic$1K
- Neuropace, Inc.$309
- Impel Pharmaceuticals Inc.$125
- Catalyst Pharmaceuticals, Inc.$17
Across 37 payments — averaging $2691.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$47K
- Medtronic$45K
- Neuropace, Inc.$8K
What the payments were for
- Consulting fees$4,55455%
- Speaking & faculty fees$1,95024%
- Travel & lodging$6558%
- Food & beverage$1,11913%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurelis, Inc. | 3 | $4,629 |
| Livanova USA, Inc. | 4 | $2,039 |
| Medtronic(2 entities) | 10 | $1,175 |
| Neuropace, Inc. | 3 | $309 |
| Impel Pharmaceuticals Inc. | 2 | $125 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VALTOCO$4,554
- VNS Therapy$1,950
- ACTIVA$750
- RNS Neurostimulator Kit$289
- PERCEPT PC BRAINSENSE$161
How this compares
$8,294 in reported general payments places this provider in the 80th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 344 | $524,188 |
| EpidiolexCannabidiol (Cbd) | 56 | $303,283 |
| OnfiClobazam | 36 | $167,433 |
| BriviactBrivaracetam | 78 | $152,057 |
| LamictalLamotrigine | 93 | $101,952 |
| KeppraLevetiracetam | 40 | $74,647 |
| VimpatLacosamide | 33 | $68,939 |
| ZonegranZonisamide | 17 | $67,902 |
| AptiomEslicarbazepine Acetate | 32 | $63,874 |
| NayzilamMidazolam | 64 | $58,232 |
| FycompaPerampanel | 37 | $45,537 |
| Lamictal XrLamotrigine | 11 | $34,667 |
| Lacosamide | 184 | $31,700 |
| LyricaPregabalin | 11 | $21,754 |
| Depakote ErDivalproex Sodium | 35 | $21,034 |
Paid to pharmacies, not to this prescriber.
Other neurology in Chicago
- Augusto MiravalleChicago$1.4M
- Adil JavedChicago$584K
- Danny BegaChicago$442K
- Michael SmithChicago$382K
- Dusan StefoskiChicago$294K
- Veronica CiprianiChicago$289K
- Thomas ShoemakerChicago$278K
- Bruce CohenChicago$276K
- Margaret ParkChicago$245K
- Leonard Verhagen MetmanChicago$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.